Basilea-Astellas' antifungal treatment gets orphan status from FDA

05/29/2013 | Pharmaceutical Business Review Online

The FDA granted orphan-drug designation to Basilea Pharmaceutica and Astellas Pharma's experimental antifungal isavuconazole as a treatment for invasive aspergillosis. The intravenous and oral-broad spectrum drug is in late-stage studies for severe invasive fungal infections.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA